<< Вернуться к списку статей журнала

Том 6 №3 2004 год - Нефрология и диализ

Механизмы нефросклефоза; фармакологическая ингибиция внутрипочечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата (Обзор литературы)

Томилина Н.А. Багдасарян А.Р.

Аннотация: Вопрос о механизмах прогрессирования хронических заболеваний почек является одним из центральных в современной нефрологии. На протяжении последних двух с половиной десятилетий его изучение ознаменовалось рядом открытий, которые позволили сформулировать современную концепцию патогенеза нефросклероза. Стало очевидным, в частности, что прогрессирование любых хронических заболеваний почек, независимо от их природы, определяется действием совокупности одних и тех же клеточных и молекулярных механизмов, которые с биологической точки зрения представляют собой комплекс процессов, направленных на репарацию тканей организма в ответ на их повреждение [101, 102].

Для цитирования: Томилина Н.А., Багдасарян А.Р. Механизмы нефросклефоза; фармакологическая ингибиция внутрипочечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата (Обзор литературы). Нефрология и диализ. 2004. 6(3):226-234. doi:

Весь текст

Ключевые слова: ингибиторы АПФ, нефропротекция, нативные почки и трансплантат

Список литературы:

1. Багдасарян А.Р. Эффективность ингибиторов ангиотензин-превращающего фермента для торможения прогрессирования хронической трансплантационной нефропатии. Автореф. дисс. … канд. мед. наук. М.: 2004.
2. Есаян А.М., Каюков И.Г., Титова В.А. Влияние ангиотензин-конвертирующего фермента эналаприла на темпы прогрессирования хронической почечной недостаточности у больных с различной степенью нарушений функционального состояния почек. Терапевтический архив 1995; 6: 57-59.
3. Кутырина И.М., Тареева И.Е., Шестакова М.В. и др. Антипротеинурическое действие ингибиторов ангиотензин-превращающего фермента при хроническом гломерулонефрите и диабетической нефропатии. Терапевтический архив 1994; 66; 6: 19-22.
4. Кутырина И.М., Лившиц Н.Л., Рогов В.А. и др. Применение ингибиторов ангиотензинпревращающего фермента при хронической почечной недостаточности. Терапевтический архив 2002; 74; 6: 34-39.
5. Кутырина И.М. Нефрологические эффекты ангиотензина II и его блокады. М.: Успехи нефрологии 2001: 94-102.
6. Медведева Т.Ю. Влияние препаратов, блокирующих ренин-ангиотензиновую систему, на прогрессирование почечной недостаточности в клинике и эксперименте. Автореферат дисс. … канд. мед. наук. М.: 2001.
7. Оконова Е.Б. Влияние блокады ренин-ангиотензиноваой системы на протеинурию и темп прогрессирования хронического гломерулонефрита. Автореферат дисс. … канд. мед. наук. М.: 2000.
8. Плиева О.К. Влияние препаратов с антипротеинурическим действием на экскрецию с мочой больных гломерулонефритом факторов эндотелия и локально-почечного фибринолиза. Автореферат дисс. … канд. мед. наук. М.: 2003.
9. Тареева И.Е., Кутырина И.М., Николаев А.Ю. и др. Пути торможения развития хронической почечной недостаточности. Терапевтический архив 2000; 72; 6: 9-14.
10. Шестакова М.В., Мухин Н.А., Дедов И.И. и др. Восстановление фильтрационной функции почек у больных сахарным диабетом при лечении каптоприлом. Терапевтический архив 1991; 72; 6: 50-55.
11. Шестакова М.В. Нефропротекция: роль артериального давления в прогрессировании патологии почек. Зависит ли нефропротективный эффект от выбора антигипертензивного препарата? Терапевтический архив 2001; 73; 6: 64-67.
12. Швецов М.Ю. Блокаторы рецепторов ангиотензина II - первый опыт и перспективы применения в нефрологии. Терапевтический архив 2002; 72; 6: 73-79.
13. Швецов М.Ю., Медведева Т.Ю., Козловская Н.Г. и др. Опыт применения валсартана с целью торможения прогрессирования почечной недостаточности у больных хроническим гломерулонефритом. Терапевтический архив 2001; 73; 6: 55-61.
14. Швецов М.Ю., Медведева Т.Ю., Оконова Е.Б. и др. Блокаторы ангиотензиновых рецепторов I типа и перспективы нефропротективной терапии. Успехи нефрологии. М.: Сборник врача 2001: 119-139.
15. Agard C.D., Garcia-Puig J., Charbonnel B. et al. Greater reduction of urinary albumin excression in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-192.
16. Ahmad J., Siddiqui M.A., Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabets Care 1997; 20: 1576-1581.
17. Altiparmack M.R., Trablus S., Apaydin S. et al. Is losartan as effective as Enalapril on Posttransplant Persistent Proteinuria? Transplant Proc 2001; 33: 368-3369.
18. Amuchastegui S.C., Azzollini N., Mister M. et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998; 9: 1948-1955.
19. Anderson S., Rennke H.G., Garsia D.L., Brenner B.M. Short and long-term effects of antihypertensive therapy in diabetic rats. Kidney Int 1989; 36: 526-536.
20. Anderson S., Meyer T.W., Rennke H.G., Brenner B.M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619.
21. Anderson S., Rennke H.G., Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rats. J Clin Invest 1986; 77: 1993-2000.
22. Andreucci V., Gallieni M., Brancaccio D. et al. AСЕ-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research. Nephrology 1998; 11; 3: 105-109.
23. Apperloo A.J., Rensma P.L. Effect of benazepril in chronic renal insufficiency. NEJM August 22, 1996; 335; 8: 596-598.
24. Asberg A., Midvedt K., Vassboth T. et al. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant 2001; 16; 7: 1465-1470.
25. Bochicchio T., Sandoval G., Ron O. et al. Fosinopril prevents hyperfiltration and decreases proteinuria in posttransplant hypertensives. Kidney Int 1990; 38; 5: 873-879.
26. Border W.A., Noble N.A. TGF-β in kidney fibrosis: A target for gene therapy. Kidney Int 1997; 51: 1388-1396.
27. Brenner B.M. Mechanisms of progression of renal disease. Международный семинар по нефрологии. М.: 1995: 127-134.
28. Brenner B.M., Meyer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. NEJM 1982; 307: 652-659.
29. Brenner B.M., Zagrobelny J.A. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting enzyme inhibitors. Kidney Int 2003; 63; Suppl 83: 77-85.
30. Brenner B.M., Cooper M.E., de Zeeuw D. et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J R A A S 2000; 1: 328-325.
31. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM 2001; 345: 861-869.
32. Burnier M., Brunner H.R. Angiotensin II receptor antagonists in hypertension. Kidney Int 1998; 54; Suppl 68: 107-111.
33. Calvino J., Lens X.M., Romero R. et al. Long-term antiproteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephron Dial Transplant 2000; 15: 82-86.
34. Campbell R., Sangalli F., Perticucci E. et al. Effects of combined ACE-inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094-1103.
35. Campistol J.M., Inigo P., Larios S. et al. Role of transforming growth factor-в1 in the progression of chronic allograft nephropathy. Nephron Dial Transplant 2001; 16; Suppl 1: 114-116.
36. Campistol J.M., Inigo P., Jimenez W. et al. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719.
37. Cao Z., Bonnet F., Candino R. et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002; 13: 1773-1787.
38. Castillo D., Campistol J.M., Guirado L. et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 54; Suppl 68: 135-139.
39. Cinotti G.A., Zucchelli P.C. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephron Dial Transplant 2001; 16; 5: 961-966.
40. Cuhaci B., Kumar M.S., Bloom R.D. et al. Transforming growth factor-b levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation September 27, 1999; 68; 6: 785-790.
41. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597.
42. Ersoy A., Dilek K., Usta M. et al. Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Transplant 2002; 16; 3: 202-205.
43. Fernandez-Andrade C., Russo D., Inversen B. et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998; 54; Suppl 68: 120-124.
44. Fine L.G., Bandyopadhay D., Norman J.T. Is there a common mechanism for the progression of different types of renal disease other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000; 57; Suppl 75: 22-26.
45. Fogo A., Ichikawa I. Angiogenic action of angiotensin II is important for the glomerular growth of maturing kidneys. Kidney Int 1991; 39: Suppl 32: 37-38.
46. Fogo A. Internephron heterogeneity of growth factors and sclerosis. Kidney Int 1994; 45; Suppl 45: 24-26.
47. Fogo A. Progression and potential regression of glomerulosclerosis. Kidney Int 2001; 59: 804-819.
48. Fogo A., Hawkins E.P., Berry P.L. et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990; 38: 115-123.
49. Fogo A. Glomerular hypertension, abnormal glomerular growth, and progression of renal disease. Kidney Int 2000; 57; Suppl 75: 15-21.
50. Fukagawa M., Noda M., Shimutzu T. et al. Chronic progressive interstitial fibrosis in renal disease - are there novel pharmacological approaches. Nephrol Dial Transplant 1999; 14: 2793-2795.
51. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitor on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-converting-enzyme inhibition and progressive renal disease study group. Ann Intern Med Sep 1, 1997; 127; 5: 337-345.
52. Grekas S.D., Dioudis C., Kalevrosoglou I. et al. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. Clin Nephrol 1995; 44; 5: 299-302.
53. Grekas D., Dioudis C., Kalevrosoglou I. et al. Renal hemodynamics in hypertensive renal allograft recipients: Effects of calcium antagonists and ACE inhibitors. Kidney Int 1996; l; 49; Suppl 55: 97-100.
54. Hannedouche T., Landais P., Goldman B. et al. Randomised controlled trial of enalapril and в blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-837.
55. Hausberg M., Kosch M., Hohage H. et al. Antihypertensive treatment in renal transplant patients - is there a role for ACE inhibitors? Ann Tranplant 2001; 6; 4: 31-37.
56. Hausberg M., Barenbrock M., Hohage H. et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33; 3: 862-868.
57. Hemmelder M., de Zeeuw D., de Jong P. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephron Dial Transplant 1999; 14; 98-104.
58. Herlitz H., Harris K. Risler T. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephron Dial Transplant 2001; 16: 2158-2165.
59. Hetzel G.R., Grunberg W., Oszan F., Brause M. et al. Angiotensin receptor antagonism in patients after renal transplantation: effect on glomerular function and TGF-β1 plasma level.
60. Holgado R., Anaya F., Del Castillo D. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephron Dial Transplant 2001; 16; Suppl 1: 117-120.
61. Horvarth L.Z., Friess H., Schilling M. et al. Altered expression of transforming growth factor - вs in chronic renal rejection. Kidney Int 1996; 50: 489-498.
62. Hostetter T.H., Olson J.L., Rennke H. et al. Hyperfiltration in remnant nephrons. A potentially adverse response to renal ablation. Am J Physiol 1981; 241: 85-93.
63. Inigo P., Campistol J.M., Lario S. Effects of losartan and amlodipine on intrarenal hemodynamic and TGF-β1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-827.
64. Isaka Y., Akagi Y., Ando Y. et al. Cytokines and glomerulosclerosis. Nephron Dial Transplant 1999; 14: Suppl 1: 30-32.
65. Jafar T.H., Schmid C.H., Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001; 135: 73-87.
66. Kagami S., Border W.A., Noble N.A. et al. Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest 1993; 69: 68-76.
67. Kincaid-Smith P., Fairley K., Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597-601.
68. Klahr S. Prevention of progression of renal nephropathy. Nephron Dial Transplant 1997; 12; Suppl 2: 63-66.
69. Klahr S., Morrissey J.J. Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31: 171-176.
70. Klahr S., Morrissey J.J. Тhe role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 57; Suppl 75: 7-14.
71. Klahr S., Morrissey J.J. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 1997; 52; Suppl 63: 111-114.
72. Lafayette R.A., Mayer G., Park S.K. et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass therapeutic advantages. J Clin Invest 1992; 90: 766-771.
73. Laverman G.D., Navis G., Henning R.H. et al. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020-1025.
74. Lewis E.J., Hunsicker L.G., Bain R.P. et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. NEJM 1993; 329: 1456-1462.
75. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEJM 2001; 345: 851-860.
76. Lin J., Valeri A.M., Markowitz G.S. et al. Angiotensin-converting enzyme inhibition in chronic allograft nephropathy. Transplantation Mar. 15, 2002; 73: 783-788.
77. Locatelli F., Del Vecchio L., Andrulli S. et al. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int 2002; 62; Suppl 82: 53-60.
78. Locatelli F., Carbarns I.R., Maschio G., Mann J.F., Ponticelli C., Ritz E. et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int 1997; 52; Suppl 63: 63-66.
79. Lufft V., Kliem V., Hamkens A. et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998; 12; 5: 409-415.
80. Luno J., Barrio V., Goicoechea M.A. et al. Effect of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002; 62; Suppl 82: 47-52.
81. Martinez-Castelao A., Hueso M., Sanz V. et al. Treatment of hypertension after renal transplantation: Long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998; 54; Suppl 68: 130-140.
82. Maschio G., Alberti D., Locatelli F. et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999; 33; Suppl 1: 16-20.
83. Maschio G., Alberti D., Locatelli F. et al. Effect of the angiotensin-converting enzyme inhibitors benazepril on the progression of chronic renal insufficiency. NEJM 1996; 334; 15: 939-945.
84. Midtvert K., Hartmann A., Foss A. et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation Dec. 15, 2001; 72; 11: 1787-1792.
85. Midvedt K., Hartmann A., Holdaas H. et al. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clin Transplant 2001; 15; 6: 426-431.
86. Mora-Macia J., Cases A., Calero K. et al. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure. Nephrol Dial Transplant 2001; 16; Suppl 1: 82-84.
87. Morrissey J.J., Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. A J Physiol - Renal Physiology 1999; 276; Issue 1: 39-45.
88. El Nahas A.M. Mechanisms of experimental and clinical renal scarring. Oxford Textbook of Clinical Nephrology ed. Davison, Cameron et al. 1998; 3: 1749-1776.
89. El Nahas A.M. Glomerulosclerosis: intrinsic and extrinsic pathways. Nephrol Dial Transplant 1996; 11: 773-777.
90. El Nahas A.M. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995; 10; Suppl 9: 28-32.
91. Nielsen S., Dollerup J., Nielsen B. et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months. Nephrol Dial Transplant 1997; 12: Suppl 2: 19-23.
92. Olson J.L., Urdaneta A.G., Heptinstall R.H. Glomerular hyalinosis and its relation to hyperfiltration. Lab Invest 1985; 42; 4: 387-398.
93. Ots M., Mackenzie H.S., Troy J.L. et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol March 4, 1997: 224-230.
94. Parving H.H., Anderson A.R., Smidt U.M. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. British Med J 1987; 294: 1443-1447.
95. Parving H.H. Prevalence and cause of albuminuria in noninsulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762.
96. Paul L.C., Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995; 52: 89-92.
97. Peters H., Noble N.A., Border W.A. Targeting TGF-β overexpression in renal disease: maximazing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1575-1583.
98. Plum J., Bunten B., Nemeth R et al. Effect of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223-2234.
99. Raine A. E. Does antihipertensive therapy modify chronic allograft failure? Kidney Int Dec, 1995; 52: 107-111.
100. Ram C.V., Vergne-Marini P. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease. Curr Hypertens Rep 1999; 1; 5: 431-435.
101. Razzaque M.S., Taguchi T. Renal fibrosis. Factors that influence and contribute to the regulation of fibrosis. Contributions to Nephrology. Editors: Razzaque M.S., Taguchi T. 2003; 139: 1-2.
102. Razzaque M.S., Azouz A., Taguchi T. Renal fibrosis. Factors regulating the progression of hypertensive nephrosclerosis. Contributions to Nephrology. Editors: Razzaque M.S., Taguchi T. 2003; 139: 173-187.
103. Remuzzi G. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet June 28, 1997; 349: 1857-1863.
104. Remuzzi G. ACE inhibitors and AT1 receptor antagonists: Is two better than one? Kidney Int 2002; 61: 1545-1547.
105. Remuzzi G. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62: 885-894.
106. Remuzzi G., Perna A., Benini R. et al. In chronic nephropathies prolonged ACE inhibition can induce remission:dynamics of time-dependent changes in GRF. J Am Soc Nephrol 1999; 10: 997-1006.
107. 107 Remuzzi G., Perico W. Routine renin-angiotensine system blockade in renal transplantation? Curr Opin Nephrol Hypertens Jan, 2002; 11; 1: 1-10.
108. Rostoker G., Ben Maadi A., Remy P. et al. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment. Nephrol Dial Transplant 1995; 10: 25-29.
109. Ruggenenti P., Perna F., Geradi G. Renal function and requirement for dialysis in chronic nephropathy patients in long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252-1256.
110. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet May 19, 2001; 357: 1601-1608.
111. Ruilope L.M., Aldiger J.C., Ponticelli C. et al. Safety of combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18; 1: 89-95.
112. Rustom R., Paraoan M.T., Sells R.A. et al. Effect of Angiotensin-Converting-Enzyme Inhibitors on Progression to End Stage Renal Failure in Chronic Vascular Rejection. Transplant Proceedings 2001; 33: 1175-1176.
113. Sennesael J., Lamote J., Violet I. et al. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipient. Hypertension Sep., 1995; 26; 3: 436-444.
114. Shihab F.S., Bennet W.M., Tanner A.M. et al. Angiotensin II blokade decreses TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-1913.
115. Shihab F.S., Tanner A.M., Shao Y. et al. Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904-2673.
116. Smit-van Oosten A., Navis G., Stegeman C.A. et al. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol May, 2001; 194; 1: 122-129.
117. Stigant C.E., Cohen J., Vivera M. et al. ACE-inhibitors and angiotensin II-antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35; 1: 154-156.
118. Szabo A., Lutz J., Scheimer K. et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Am J Kidney Dis 2001; 37; 4: 866-870.
119. Tall M., Brenner B.B. Renoprotective benefits of RAS inhibition: from ACEi to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
120. Tall M.W., Chertow G.M., Rennke H.G. et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Renal Physiol 2001; 280; Issue 2: 343-355.
121. Tomooka S., Border W.A., Marshall B.C. et al. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992; 42: 1462-1469.
122. Traindl O., Falger S., Reading S. et al. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993; 55; 6: 1309-1313.
123. Trevisan R., Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876-883.
124. Wolf G. The Renin-Angiotensin System and Progression of Renal Disease. Editor G. Wolf. Contributions to Nephrology 2001.
125. Wolf G., Ziyadeh F.N., Thaiss F. et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. J Clin Invest 1997; 100: 1047-1058.
126. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol Dial Transplant 1999; 14; Suppl 1: 42-44.
127. Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998; 13: 1131-1142.
128. Yoshida Y., Fogo A., Ichikawa I. Glomerular hemodynamic changes versus hyperthrophy in experimental glomerular sclerosis. Kidney Int 1989; 35: 664-660.
129. Yoshida Y., Kawamura T., Ikoma M. et al. Effects of antihypertensive drug on glomerular morfology. Kidney Int 1989; 36: 626-635.
130. Zia F., Nagano H., Kusaka M. et al. Renal allograft protection with losartan in Fisher-Lewis rats: Hemodynamics, macrophages, and cytokines. Kidney Int 2000; 57: 55-59.

Другие статьи по теме

• Сравнительная оценка влияния монои комбинированной терапии периндоприлом и амлодипином на ремоделирование миокарда левого желудочка у больных на гемодиализе
• Ангиотензин II - современное представление о патогенезе нефросклероза (Обзор литературы)
• Ингибиторы ангиотензин-конвертирующего фермента и блокаторы рецепторов ангиотензина II: уникальные препараты для защиты почки и сердечно-сосудистой системы
• Артериальная гипертензия при ХБП: от начальных до продвинутых стадий. Диагностические и терапевтические стратегии. Часть 1. Артериальная гипертензия у пациентов с ХБП 1-4 стадий